| Title |
Aripiprazole alone or in combination for acute mania
|
|---|---|
| Published in |
Cochrane database of systematic reviews, December 2013
|
| DOI | 10.1002/14651858.cd005000.pub2 |
| Pubmed ID | |
| Authors |
Rachel Brown, Matthew J Taylor, John Geddes |
| Abstract |
Bipolar disorder is a mental disorder characterised by episodes of elevated or irritable mood (manic or hypomanic episodes) and episodes of low mood and loss of energy (depressive episodes). Drug treatment is the first-line treatment for acute mania with the initial aim of rapid control of agitation, aggression and dangerous behaviour. Aripiprazole, an atypical antipsychotic, is used in the treatment of mania both as monotherapy and combined with other medicines. The British Association of Psychopharmacology guidelines report that, in monotherapy placebo-controlled trials, the atypical antipsychotics, including aripiprazole, have been shown to be effective for acute manic or mixed episodes. |
X Demographics
The data shown below were collected from the profiles of 7 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 1 | 14% |
| Canada | 1 | 14% |
| Spain | 1 | 14% |
| Unknown | 4 | 57% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 7 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 362 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | <1% |
| Colombia | 1 | <1% |
| Netherlands | 1 | <1% |
| South Africa | 1 | <1% |
| Unknown | 358 | 99% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 55 | 15% |
| Researcher | 45 | 12% |
| Student > Bachelor | 36 | 10% |
| Student > Ph. D. Student | 31 | 9% |
| Student > Doctoral Student | 25 | 7% |
| Other | 71 | 20% |
| Unknown | 99 | 27% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 122 | 34% |
| Psychology | 43 | 12% |
| Nursing and Health Professions | 30 | 8% |
| Social Sciences | 11 | 3% |
| Neuroscience | 10 | 3% |
| Other | 30 | 8% |
| Unknown | 116 | 32% |
Attention Score in Context
This research output has an Altmetric Attention Score of 7. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 31 May 2023.
All research outputs
#4,729,772
of 23,900,102 outputs
Outputs from Cochrane database of systematic reviews
#7,159
of 12,767 outputs
Outputs of similar age
#50,930
of 292,429 outputs
Outputs of similar age from Cochrane database of systematic reviews
#145
of 230 outputs
Altmetric has tracked 23,900,102 research outputs across all sources so far. Compared to these this one has done well and is in the 80th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 12,767 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 33.7. This one is in the 43rd percentile – i.e., 43% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 292,429 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 82% of its contemporaries.
We're also able to compare this research output to 230 others from the same source and published within six weeks on either side of this one. This one is in the 36th percentile – i.e., 36% of its contemporaries scored the same or lower than it.